COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,687 Articles (22,913 medRxiv, 8,774 bioRxiv)

Most recent first Previous |  Page 2124: Articles 21231-21240  | Next

Susceptibility of well-differentiated airway epithelial cell cultures from domestic and wildlife animals to SARS-CoV-2
Gultom, M., Licheri, M., Laloli, L., Wider, M., Straessle, M., Steiner, S., Kratzel, A., Thao, T. T. N., Stalder, H., Portmann, J., Holwerda, M., V'kovski, P., Ebert, N., Stokar - Regenscheit, N., Gurtner, C., Zanolari, P., Posthaus, H., Schuller, S., Moreira - Soto, A., Vicente - Santos, A., Corrales - Aguilar, E., Ruggli, N., Tekes, G., von Messling, V., Sawatsky, B., Thiel, V., Dijkman, R.
10.1101/2020.11.10.374587 — Posted: 2020-11-10
In Vitro Efficacy of "Essential Iodine Drops" Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)
Kontos, Z.
10.1101/2020.11.07.370726 — Posted: 2020-11-10
Balancing quarantine and self-distancing measures in adaptive epidemic networks
Horstmeyer, L., Kuehn, C., Thurner, S.
10.1101/2020.11.07.20227595 — Posted: 2020-11-10
A fair efficacy formula for assessing the effectiveness of contact tracing applications
Fowler, A.
10.1101/2020.11.07.20227447 — Posted: 2020-11-10
Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19
Ayoub, H. H., Chemaitelly, H., Seedat, S., Makhoul, M., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., Butt, A. A., Coyle, P., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Yassine, H. M., Al Kuwari, M. G., Al Romaihi, H. E., Al-Thani, M. H., Bertollini, R., Abu-Raddad, L. J.
10.1101/2020.11.08.20184663 — Posted: 2020-11-10
Execution of intervention matters more than strategy: A lesson from the spatiotemporal assessment of COVID-19 clusters in Nepal
Acharya, B. K., Khanal, L., Mahyoub, A. S. M., Ruan, Z., Yang, Y., Adhikari, S. K., Pandit, S., Neupane, B. K., Paudel, B. K., Lin, H.
10.1101/2020.11.07.20227520 — Posted: 2020-11-10
Human cardiac stromal cells exposed to SARS-CoV-2 evolve into hyper-inflammatory/pro-fibrotic phenotype and produce infective viral particles depending on the levels of ACE2 receptor expression
Amendola, A., Garoffolo, G., Songia, P., Ferrari, S., Bernava, G., Canzano, P., Myasoedova, V., Colavita, F., Castilletti, C., Sberna, G., Capobianchi, M. R., Agrifoglio, M., Colombo, G. I., Poggio, P., Pesce, M.
10.1101/2020.11.06.20226423 — Posted: 2020-11-10
ConceptWAS: a high-throughput method for early identification of COVID-19 presenting symptoms
Zhao, J., Grabowska, M. E., Kerchberger, V. E., Smith, J. C., Eken, H. N., Feng, Q., Peterson, J. F., Rosenbloom, S. T., Johnson, K. B., Wei, W.-Q.
10.1101/2020.11.06.20227165 — Posted: 2020-11-10
A lateral flow test detecting SARS-CoV-2 neutralizing antibodies
Wang, J. J., Zhang, N., Chen, S., Wu, J. V., Yang, X.
10.1101/2020.11.05.20222596 — Posted: 2020-11-10
Temporal Variations in the Intensity of Care Provided to Community and Nursing Home Residents Who Died of COVID-19 in Ontario, Canada
Brown, K. A., Daneman, N., Buchan, S. A., Chan, A. K., Stall, N. M.
10.1101/2020.11.06.20227140 — Posted: 2020-11-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).